Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization 92% Improvement Relative Risk Case 81% Case (b) 82% Hospitalization/ER 89% Symptomatic case 81% Recovery time 62% Time to viral- 69% c19early.com/r Regeneron et al. NCT04452318 Casirivimab/i.. RCT Prophylaxis Favors casirivimab/im.. Favors control
Regeneron, 1,683 patient casirivimab/imdevimab prophylaxis RCT: 92% lower hospitalization [p=0.03], 81% fewer cases [p<0.0001], 89% fewer combined hospitalization/ER visits [p=0.06], and 81% fewer symptomatic cases [p<0.0001] https://c19p.org/regeneron5
copied to clipboard
New phase 3 analyses show that a single dose of REGEN-COV® (casirivimab and imdevimab) provides long-term protection against COVID-19
Regeneron Press Release (News), NCT04452318 (history)
8 Nov 2021    Source   PDF   Share   Tweet
Long-term results for PEP RCT NCT04452318 (history), with 841 baseline seronegative casirivimab/imdevimab patients and 842 placebo patients, showing significantly lower cases with treatment.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of hospitalization, 92.3% lower, RR 0.08, p = 0.03, treatment 0 of 841 (0.0%), control 6 of 842 (0.7%), NNT 140, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 8 months.
risk of case, 81.5% lower, RR 0.19, p < 0.001, treatment 20 of 841 (2.4%), control 108 of 842 (12.8%), NNT 9.6, months 1-8.
risk of case, 81.6% lower, RR 0.18, p < 0.001, treatment 7 of 841 (0.8%), control 38 of 842 (4.5%), NNT 27, months 2-8.
risk of hospitalization/ER, 88.9% lower, RR 0.11, p = 0.06, treatment 0 of 753 (0.0%), control 4 of 752 (0.5%), NNT 188, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 29.
risk of symptomatic case, 81.4% lower, RR 0.19, p < 0.001, treatment 11 of 753 (1.5%), control 59 of 752 (7.8%), NNT 16, day 29.
recovery time, 62.5% lower, relative time 0.37, p < 0.001, treatment 753, control 752, short-term followup, relative time with symptoms.
time to viral-, 69.2% lower, relative time 0.31, p < 0.001, treatment 753, control 752, short-term followup, relative time with high viral load.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Regeneron et al., 8 Nov 2021, Double Blind Randomized Controlled Trial, multiple countries, preprint, 1 author, trial NCT04452318 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit